The association of vitamin K status with lung function and disease in a general population

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 593 KB, PDF-dokument

Introduction: Matrix Gla protein (MGP) is an inhibitor of lung tissue calcification. The plasma level of dephosphorylated-uncarboxylated MGP (dp-ucMGP) is a biomarker of vitamin K status. The present study assessed whether lower vitamin K status (reflected by higher dp-ucMGP) was associated with lung function and lung disease/symptoms.

Methods: A general population sample of 4092 individuals, aged 24 to 77 years, underwent a health examination including questionnaires, spirometry and measurements of plasma dp-ucMGP. Associations of dp-ucMGP with lung function and self-reported disease/symptoms were estimated using regression models adjusted for age, sex and height. Associations were expressed as β-estimates or odds ratios (ORs) per doubling in dp-ucMGP.

Results: Lower vitamin K status (higher dp-ucMGP) was associated with lower forced expiratory volume in 1 s (FEV1) (98 mL; 95% CI: 54–141 mL) and lower forced vital capacity (FVC) (136 mL; 95% CI: 85–187 mL). Dp-ucMGP was not associated with the FEV1/FVC ratio (0.0 percentage points higher than the expected value; 95% CI: −1.0–1.0). Furthermore, lower vitamin K status was associated with COPD (OR 2.24, 95% CI: 1.53–3.27), wheezing (OR 1.81, 95% CI: 1.44–2.28) and asthma (OR 1.44, 95% CI: 1.12–1.83).

Conclusion: Lower vitamin K status was associated with lower ventilatory capacity (lower FEV1 and FVC), and with higher risk of self-reported asthma, COPD and wheezing. Vitamin K status was not associated with airflow obstruction (FEV1/FVC ratio).
OriginalsprogEngelsk
Artikelnummer00208-2023
Tidsskrift ERJ Open Research
Vol/bind9
Udgave nummer5
Antal sider11
ISSN2312-0541
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
Support statement: The present study was funded by a Steno Collaborative Grant 2019 from the Novo Nordisk Foundation (0058130), the Center for Clinical Research and Prevention, and by a grant from the Danish Cardiovascular Academy, which is funded by the Novo Nordisk Foundation (grant number NNF20SA0067242) and The Danish Heart Foundation. Funding information for this article has been deposited with the Crossref Funder Registry.

Publisher Copyright:
© 2023, European Respiratory Society. All rights reserved.

ID: 387830800